RedHill to receive $11.7M cash infusion

RedHill Biopharma (RDHL -0.4%) has entered into an agreement for an equity placement of $11.7M from Israeli institutional and private investors.

RedHill will use the money for R&D, including developing its RHB-104 treatment for Crohn's disease and RHB-105 for H. pylori infection, both of which are in Phase III studies, and for potential acquisitions. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs